Duration of Protective Effect From Inhaled Ipratropium Bromide on Methacholine Airway Hyperresponsiveness

University of Saskatchewan

Status and phase: Completed; Phase 4

Conditions: Asthma

Treatments: Drug: ipratropium bromide; Drug: placebo

Study type: Interventional

Funder types: Other

Identifiers

NCT00605410

BIO 07-161

Details and patient eligibility

About

Certain lung disease medications can influence diagnostic tests and research investigations. This study will investigate how long ipratropium bromide must be withheld before a methacholine challenge test can be conducted. This information will be useful for validating current guidelines.

Enrollment: 12 patients

Sex: All

Ages: 19+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosis of asthma; stable and controlled
• FEV1 greater than or equal to 65% predicted

Exclusion criteria

• Concomitant lung disease other than asthma

Trial design

Primary purpose: Diagnostic

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Triple Blind

---

12 participants in 2 patient groups, including a placebo group

1

Active Comparator group

Treatment:

Drug: ipratropium bromide

2

Placebo Comparator group

Treatment:

Drug: placebo